Click here to view online. Add this email to your safelist.

AstraZeneca logo

Nirsevimab MEDLEY Phase II/III trial demonstrated favourable safety and tolerability profile in infants at high risk of RSV

28 June 2021

The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their first RSV season.

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2021

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.